Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls
Session Wins ATC’s People’s Choice AwardLund, Sweden, June 7, 2019 - Hansa Biopharma AB (”Hansa”) (NASDAQ Stockholm: HNSA ), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIXTM (imlifidase), the company’s novel IgG-degrading enzyme, was highlighted in three presentations at the 2019 American Transplant Congress (ATC), which was held from June 1 – 5, 2019 in Boston, Massachusetts, USA. In a plenary presentation on June 5, 2019, Dr. Edmund Huang, MD,